Pharmacotherapy of social anxiety disorder: What does the evidence tell us?

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 12, 2006, Pages 20-26

  Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ATENOLOL; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BROMAZEPAM; CALCIUM CHANNEL BLOCKING AGENT; CLONAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PAROXETINE; PHENELZINE; PREGABALIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ABNORMAL THINKING; AVOIDANCE BEHAVIOR; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED DRUG RELEASE; DEPRESSION; DISEASE SEVERITY; DISTRESS SYNDROME; DIZZINESS; DOSE RESPONSE; EVIDENCE BASED MEDICINE; FATIGUE; FEAR; HEADACHE; HUMAN; HYPERHIDROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVIEW; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

CLONAZEPAM; COMORBIDITY; DRUG THERAPY, COMBINATION; HUMANS; PAROXETINE; PHOBIC DISORDERS; PSYCHOTROPIC DRUGS; RECURRENCE; SERTRALINE; TREATMENT OUTCOME;

EID: 33751548280     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-288
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
3. Turner SM, Beidel DC, Townsley RM. Social phobia: a comparison of specific and generalized subtypes and avoidant personality disorder. J Abnorm Psychol 1992;101:326-331
4. Beidel DC, Christ MG, Long PJ. Somatic complaints in anxious children. J Abnorm Child Psychol 1991;19:659-670
5. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713
6. Lydiard RB, Bobes J. Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depress Anxiety 2000;11:99-104
7. Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004;65:222-229
8. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281
9. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br J Psychiatry 2001;179:23-30
10. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:785-792
11. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002;22:257-262
12. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia in a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71:1058-1067
13. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in general social phobia. Arch Gen Psychiatry 2004;61:1005-1013
14. Van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: a double-blind controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128-134
15. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760
16. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-248
17. Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder. Br J Psychiatry 2005;186:222-226
18. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:488-496
19. Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005;177:280-288
20. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-396
21. Walkup J, Labellarte M, Riddle MA, et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002;12:175-188
22. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004;61:1153-1162
23. Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 2003;6:427-442
24. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-283
25. Massion AO, Dyck IR, Shea MT, et al. Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder. Arch Gen Psychiatry 2002;59:434-440
26. Slaap BR, van Vliet IM, Westenberg HG, et al. Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord 1996;39:13-19
27. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-428
28. Versiani M, Nardi AE, Figueira I, et al. Double-blind controlled trial with bromazepam in social phobia. J Brasileiro de Psiquiatria 1997;46:167-171
29. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991;48:938-945
30. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder [BRAINSTORMS]. J Clin Psychiatry 2002;63:756-757
31. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65:244-248
32. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348
33. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-149
34. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002;16:365-368
35. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 2005;19:551-553
36. Davidson JR, Foa EB, Connor KM, et al. Hyperhidrosis in social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1327-1331
37. Connor KM, Cook JL, Davidson JR. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. Presented at the 43rd annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 2004; San Juan, Puerto Rico
38. Lecrubier Y. Implications of early onset social phobia on outcome. Eur Neuropsychopharmacol 1997;7(suppl 2):S85
39. Schneier FR, Blanco C, Campeas R, et al. Escitalopram treatment of social anxiety disorder with comorbid major depression [abstract]. Neuropsychopharmacology 2004;29(suppl 1):S206
40. Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001;14:255-262
41. Stein DJ, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002;59:1111-1118
42. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20:636-644
43. Montgomery SA, Nil R, Dürr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66:1270-1278
44. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18:373-378
45. Faigel HC. The effect of beta blockade on stress-induced cognitive dysfunction in adolescents. Clin Pediatr (Phila) 1991;30:441-445
46. Elman MJ, Sugar J, Fiscella R, et al. The effect of propranolol versus placebo on resident surgical performance. Trans Am Ophthalmol Soc 1998;96:283-291
47. Drew PJ, Barnes JN, Evans SJ. The effect of acute beta-adrenoceptor blockade on examination performance. Br J Clin Pharmacol 1985;19:783-786
48. Liu HH, Milgrom P, Fiset L. Effect of a beta-adrenergic blocking agent on dental anxiety. J Dent Res 1991;70:1306-1308
49. Mealy K, Ngeh N, Gillen P, et al. Propranolol reduces the anxiety associated with day case surgery. Eur J Surg 1996;162:11-14
50. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300